Table 5.
Multiple linear regression analysis of ΔbaPWV with Δ value of other clinical parameters in the MET-DUL group
| Variables | β | SE | t value | P value | 95% CI |
|---|---|---|---|---|---|
| ΔNO | − 0.257 | 0.115 | − 3.287 | 0.026 | − 0.286 to − 0.903 |
| ΔIL-6 | 0.186 | 0.109 | 2.832 | 0.043 | 1.093 to 2.886 |
| ΔEPCs | − 0.373 | 0.147 | − 5.206 | 0.002 | − 0.305 to − 0.849 |
| ΔEPA | − 0.296 | 0.151 | − 3.749 | 0.018 | − 0.261 to − 0.919 |
| ΔEMA | − 0.215 | 0.132 | − 2.985 | 0.037 | − 0.174 to − 0.863 |
MET-DUL metformin combined with dulaglutide treatment group, baPWV brachial–ankle pulse wave velocity, NO nitric oxide, IL-6 interleukin-6, EPCs, endothelial progenitor cells, EPA, endothelial progenitor cells proliferative ability, EMA, endothelial progenitor cells migration ability, ∆ the change value of various index before and after treatment